A novel compound heterozygous tyrosine hydroxylase mutation (p.R441P) with complex phenotype
Related Experiment Video
Updated: May 8, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Kristoffer Haugarvoll1, Laurence A Bindoff
1Department of Neurology, Haukeland University Hospital, Bergen, Norway. haugarvoll@gmail.com
Abstract:
Tyrosine hydroxylase (TH) is a tetrahydrobiopterin (BH4) dependent enzyme that catalyses the conversion of L-tyrosine to L-dopa, the rate-limiting step in the biosynthesis of dopamine. Autosomal recessive mutations in the TH gene cause impaired TH activity and are associated with phenotypes ranging from autosomal recessive dopa-responsive dystonia (DRD) to progressive infantile encephalopathy. Herein, we present a patient with TH-deficiency due to two compound heterozygous missense mutations in the TH/gene, one of which is novel (p.R441P). A clinical update on TH-deficiency and clues on how to achieve a timely diagnosis of this highly treatable disorder is provided.
More Related Videos
Related Concept Videos
Epistasis
Genetic Lingo
Epistasis Analysis
Pleiotropy
Incomplete Dominance
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

